Lyme disease is a growing problem with no approved preventive solution1,2
Woman leaning against a tree.

Lyme Disease

Lyme disease is the most common vector-borne disease in the United States and, according to the Centers for Disease Control and Prevention, the areas where it is common are expanding.1,2

Person icon

More than 30 million Americans are at high or moderate risk of contracting Lyme disease.2

Health icon

Approximately 300,000-400,000 people are diagnosed with Lyme disease in the United States each year.2,3

Lyme disease is spread through blacklegged deer ticks4

Infected ticks are commonly found in the northeastern, mid-Atlantic, and northern central United States and cause Lyme disease by transmitting the bacterium Borrelia burgdorferi. The majority of humans are infected through the bite of immature ticks called nymphs, which are so small that they typically go undetected. In most cases, the tick must be attached for 36 to 48 hours or more before the Lyme disease bacterium can be transmitted.4

Blacklegged deer tick.
Patient in pain.

Lyme disease symptoms are diverse and can be devastating5

Typical symptoms of early Lyme disease include5:

  • Erythema migrans rash
  • Fever
  • Chills
  • Swollen lymph nodes
  • Headache
  • Fatigue
  • Muscle and joint aches

When left untreated, symptoms worsen and can include5:

  • Facial palsy
  • Irregular heartbeat
  • Episodes of dizziness
  • Shortness of breath
  • Nerve pain
  • Joint pain and swelling
  • Inflammation of the nervous system
  • Severe headache and neck stiffness
  • Intermittent pain in tendons, muscles, joints, and bones

Lyme disease creates a serious financial burden6

Untreated Lyme disease costs the US healthcare system up to $1.3 billion a year6

Patients can spend an average of $3000 annually in return doctor visits and testing to investigate lingering symptoms6


1. Recent surveillance data. US Centers for Disease Control and Prevention. Accessed July 6, 2021. 2. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. Tarsus Pharmaceuticals, Inc. Press release. June 16, 2021. 3. How many people get Lyme disease? US Centers for Disease Control and Prevention. Accessed July 6, 2021. 4. Transmission. US Centers for Disease Control and Prevention. Accessed July 6, 2021. 5. Signs and symptoms of untreated Lyme disease. US Centers for Disease Control and Prevention. Accessed July 6, 2021. 6. Lyme disease costs up to $1.3 billion per year to treat, study finds. Johns Hopkins Bloomberg School of Public Health. Published February 5, 2015. Accessed July 23, 2021.


There is currently no FDA-approved pharmacological option for preventing Lyme disease2

Learn about TP-05
Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Opt in to be the first to receive the latest Tarsus news
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.